Article

Novel treatment found for LHON

A novel treatment for Leber’s hereditary optic neuropathy (LHON) uses a modified virus to introduce healthy genes into the mitochondria to correct the genetic defect.

Miami-A novel treatment for Leber’s hereditary optic neuropathy (LHON) uses a modified virus to introduce healthy genes into the mitochondria to correct the genetic defect.

No cure exists for LHON. Using experimental models, however, a team led by John Guy, MD, has shown that it is safe and effective to replace mutated genes with healthy ones and that doing so can prevent deterioration of the retinal cells that form the optic nerve. To deliver the healthy genes into the mitochondria, researchers redirected the adeno-associated virus to the mitochondria rather than to its typical target, the nucleus.

“This new approach shows the vast potential for genetic-therapy applications while helping to address a significant cause of blindness,” said Dr. Guy, a professor of ophthalmology at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. Aging, cancer, and Parkinson’s disease also are caused by mutations in the mitochondria, he added.

This research demonstrates that when efficiently introduced into mitochondria, it is possible for normal DNA to correct a biochemical defect in cellular energy production and restore visual function. The investigators’ next steps will be to try incorporating all three genes that cause LHON into a single viral carrier. Dr. Guy hopes to receive FDA approval to inject therapeutic genes into patients who have visual loss from mitochondrial disease.

Two National Institutes of Health/National Eye Institute grants totaling $6.1 million funded this research, which began in 2007. Proceedings of the National Academy of Sciences published an article by Dr. Guy about the research on April 20. The article is available at www.pnas.org/content/early/2012/04/19/1119577109.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.